Phase 4 Completed N=106 Randomized Single-blind Treatment

Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues

Open-angle glaucoma · Hypertension

Source: ClinicalTrials.gov NCT00539526 ↗

Enrolled (actual)

106

Serious AEs

0.0%

Results posted

Oct 2011

Primary outcomePrimary: Change From Baseline in Mean Conjunctival Hyperemia Scores at Month 3 — 0.74; 0.86; 0.74; 0.05 Scores on Scale

Summary

This study will evaluate hyperemia and ocular surface tolerability in patients on prostaglandin analogues

Outcome Measures

Outcome	Result	p-value
PRIMARY Change From Baseline in Mean Conjunctival Hyperemia Scores at Month 3	0.74; 0.86; 0.74; 0.05; 0.07; 0.06	—
SECONDARY Change From Baseline in Corneal Staining With Fluorescein at Month 3	0.59; 0.48; 0.70; 0.15; -0.07; -0.18	—
SECONDARY Change From Baseline in Tear Break-Up Time (TBUT) at Month 3	9.1; 7.9; 8.6; 0.5; 1.7; 0.4	—

Eligibility Criteria

Inclusion Criteria

Diagnosis of open-angle glaucoma (pseudoexfoliative or pigmentary glaucomas are allowed) or ocular hypertension

Exclusion Criteria

Known contraindication to latanoprost, bimatoprost or travoprost
Uncontrolled systemic disease
Active ocular disease other than glaucoma or ocular hypertension
Pregnant or lactating women or women of childbearing potential NOT utilizing a medically acceptable form of birth control

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00539526). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.